Literature DB >> 15007106

Obligatory role for endogenous endothelin in mediating the hypertrophic effects of phenylephrine and angiotensin II in neonatal rat ventricular myocytes: evidence for two distinct mechanisms for endothelin regulation.

Ying Xia1, Morris Karmazyn.   

Abstract

Various Gq protein-coupled receptor agonists such as the alpha1 adrenoceptor agonist phenylephrine, angiotensin II, and endothelin-1 are potent hypertrophic factors. There is evidence of potential cross talk between these agents, particularly in terms of endothelin-1 as playing a central role in mediating the actions of other hypertrophic factors. Using cultured rat neonatal ventricular myocytes, we assessed the potential cross talk between these factors and sought to examine the potential underlying mechanisms. Twenty-four-hour exposure to either agent produced significant hypertrophy as determined by cell size and molecular markers. Although the hypertrophic effects of phenylephrine and angiotensin II were expectedly prevented by alpha1 and AT1 receptor antagonists, respectively, these effects were also blocked by the ETA receptor antagonist BQ123 [cyclo(D-Asp-Pro-D-Val-Leu-D-Trp)] but not by the ETB antagonist BQ788 (N-cis-2,6-dimethylpiperidinocarbonyl-L-gamma-methylleucyl-D-1-methoxycarbonyltryptophanyl-D-norleucine). Both phenylephrine and angiotensin II significantly increased protein expression of both endothelin receptor subtypes. Both phenylephrine and angiotensin II produced significant activation of p38 as well as extracellular signal-regulated protein kinase and c-Jun NH2-terminal kinase, although this was unaffected by endothelin receptor blockade. Further studies revealed that the effects of phenylephrine and angiotensin II were mediated by stimulated endothelin-1 production occurring via two separate mechanisms: angiotensin II by increasing the levels of the endothelin-1 precursor prepro endothelin-1 and phenylephrine by upregulating endothelin-converting enzyme 1. Our results indicate that the endothelin-1 system plays an obligatory role in the hypertrophic response to both phenylephrine and angiotensin II in cultured myocytes through a mechanism independent of mitogenactivated protein kinase activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15007106     DOI: 10.1124/jpet.104.065185

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Dietary sodium modulates the interaction between efferent renal sympathetic nerve activity and afferent renal nerve activity: role of endothelin.

Authors:  Ulla C Kopp; Olaf Grisk; Michael Z Cicha; Lori A Smith; Antje Steinbach; Torsten Schlüter; Nicole Mähler; Tomas Hökfelt
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-05-27       Impact factor: 3.619

2.  Activation of endothelin A receptors contributes to impaired responsiveness of renal mechanosensory nerves in congestive heart failure.

Authors:  Ulla C Kopp; Michael Z Cicha; Susan Y Jones
Journal:  Can J Physiol Pharmacol       Date:  2010-06       Impact factor: 2.273

3.  Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension.

Authors:  Gaurav Choudhary; Frederick Troncales; Douglas Martin; Elizabeth O Harrington; James R Klinger
Journal:  J Heart Lung Transplant       Date:  2011-05-08       Impact factor: 10.247

4.  Estrogen inhibits cardiomyocyte hypertrophy in vitro. Antagonism of calcineurin-related hypertrophy through induction of MCIP1.

Authors:  Ali Pedram; Mahnaz Razandi; Mark Aitkenhead; Ellis R Levin
Journal:  J Biol Chem       Date:  2005-05-16       Impact factor: 5.157

5.  Role of NF-κB and p38 MAPK activation in mediating angiotensin II and endothelin-1-induced stimulation in leptin production and cardiomyocyte hypertrophy.

Authors:  Venkatesh Rajapurohitam; Ana Kilic; Sabzali Javadov; Morris Karmazyn
Journal:  Mol Cell Biochem       Date:  2012-04-20       Impact factor: 3.396

6.  Scutellarein protects against cardiac hypertrophy via suppressing TRAF2/NF-κB signaling pathway.

Authors:  Xiujuan Shi; Yongjia Hu; Yuxiong Jiang; Jiawen Wu; Chen Zhang; Jieping Zhang; Shengyu Wu; Yingshi Wu; Weibing Dong; Jue Li
Journal:  Mol Biol Rep       Date:  2022-01-06       Impact factor: 2.316

Review 7.  Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies.

Authors:  John W Wright; Shigehiko Mizutani; Joseph W Harding
Journal:  Heart Fail Rev       Date:  2007-11-07       Impact factor: 4.214

8.  Resistance to cardiomyocyte hypertrophy in ae3-/- mice, deficient in the AE3 Cl-/HCO3- exchanger.

Authors:  Daniel Sowah; Brittany F Brown; Anita Quon; Bernardo V Alvarez; Joseph R Casey
Journal:  BMC Cardiovasc Disord       Date:  2014-07-21       Impact factor: 2.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.